These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 19576193

  • 1. Clinical value of M22-based assays for TSH-receptor antibody (TRAb) in the follow-up of antithyroid drug treated Graves' disease: comparison with the second generation human TRAb assay.
    Massart C, Gibassier J, d'Herbomez M.
    Clin Chim Acta; 2009 Sep; 407(1-2):62-6. PubMed ID: 19576193
    [Abstract] [Full Text] [Related]

  • 2. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease.
    Schott M, Morgenthaler NG, Fritzen R, Feldkamp J, Willenberg HS, Scherbaum WA, Seissler J.
    Horm Metab Res; 2004 Feb; 36(2):92-6. PubMed ID: 15002058
    [Abstract] [Full Text] [Related]

  • 3. Comparison of M22-based ELISA and human-TSH-receptor-based luminescence assay for the measurement of thyrotropin receptor antibodies in patients with thyroid diseases.
    Liu C, Hermsen D, Domberg J, Graeber C, Hautzel H, Duan Y, Xu KF, Liu CP, Mao XD, Cupisti K, Scherbaum WA, Schott M.
    Horm Metab Res; 2008 Jul; 40(7):479-83. PubMed ID: 18504673
    [Abstract] [Full Text] [Related]

  • 4. TSH receptor antibody (TRAb) assays based on the human monoclonal autoantibody M22 are more sensitive than bovine TSH based assays.
    Zöphel K, Roggenbuck D, von Landenberg P, Wunderlich G, Grüning T, Kotzerke J, Lackner KJ, Rees Smith B.
    Horm Metab Res; 2010 Jan; 42(1):65-9. PubMed ID: 19830651
    [Abstract] [Full Text] [Related]

  • 5. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
    Quadbeck B, Hoermann R, Hahn S, Roggenbuck U, Mann K, Janssen OE.
    Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
    [Abstract] [Full Text] [Related]

  • 6. Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment.
    Wallaschofski H, Miehle K, Mayer A, Tuschy U, Hentschel B, Paschke R.
    Horm Metab Res; 2002 Jul; 34(7):383-8. PubMed ID: 12189586
    [Abstract] [Full Text] [Related]

  • 7. [New assays of TSH-receptor antibodies: analytical and clinical performances in the diagnosis of Graves' disease].
    Massart C, Sapin R, Gibassier J, Agin A, d'Herbomez M.
    Ann Biol Clin (Paris); 2009 Jul; 67(6):661-7. PubMed ID: 19939769
    [Abstract] [Full Text] [Related]

  • 8. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B, Hoermann R, Roggenbuck U, Hahn S, Mann K, Janssen OE, Basedow Study Group.
    Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
    [Abstract] [Full Text] [Related]

  • 9. [Antibodies against TSH receptors (TRAb) as indicators in prognosing the effectiveness of Tiamazol therapy for Grave's Disease].
    Bojarska-Szmygin A, Ciechanek R.
    Wiad Lek; 2003 Sep; 56(7-8):303-7. PubMed ID: 14969154
    [Abstract] [Full Text] [Related]

  • 10. [Individual outcome monitoring of TSH receptor antibody level for predicting the prognosis of Graves' disease].
    Rink T, Holle LH, Schroth HJ, Garth H.
    Nuklearmedizin; 1998 May; 37(3):90-4. PubMed ID: 9604228
    [Abstract] [Full Text] [Related]

  • 11. Clinical value of the first automated TSH receptor autoantibody assay for the diagnosis of Graves' disease (GD): an international multicentre trial.
    Schott M, Hermsen D, Broecker-Preuss M, Casati M, Mas JC, Eckstein A, Gassner D, Golla R, Graeber C, van Helden J, Inomata K, Jarausch J, Kratzsch J, Miyazaki N, Moreno MA, Murakami T, Roth HJ, Stock W, Noh JY, Scherbaum WA, Mann K.
    Clin Endocrinol (Oxf); 2009 Oct; 71(4):566-73. PubMed ID: 19170704
    [Abstract] [Full Text] [Related]

  • 12. Improved prediction of relapse of Graves' thyrotoxicosis by combined determination of TSH receptor and thyroperoxidase antibodies.
    Schott M, Eckstein A, Willenberg HS, Nguyen TB, Morgenthaler NG, Scherbaum WA.
    Horm Metab Res; 2007 Jan; 39(1):56-61. PubMed ID: 17226115
    [Abstract] [Full Text] [Related]

  • 13. Impact of smoking on the course of Graves' disease after withdrawal of antithyroid drugs.
    Quadbeck B, Roggenbuck U, Janssen OE, Hahn S, Mann K, Hoermann R, Basedow Study Group.
    Exp Clin Endocrinol Diabetes; 2006 Sep; 114(8):406-11. PubMed ID: 17039420
    [Abstract] [Full Text] [Related]

  • 14. Changes in TSH receptor antibody levels (TRAb) as markers of effectiveness of various therapies in Graves-Basedow's disease.
    Bojarska-Szmygin A, Janicki K, Pietura R, Janicka L.
    Ann Univ Mariae Curie Sklodowska Med; 2003 Sep; 58(1):248-53. PubMed ID: 15314994
    [Abstract] [Full Text] [Related]

  • 15. High cut-off value of a chimeric TSH receptor (Mc4)-based bioassay may improve prediction of relapse in Graves' disease for 12 months.
    Hwang S, Shin DY, Song MK, Lee EJ.
    Endocrine; 2015 Feb; 48(1):89-95. PubMed ID: 24968734
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of the 2nd generation radio-receptional assay for anti-TSH receptor antibodies (TRAb) in autoimmune thyroid diseases. Comparison with 1st generation and anti-thyroperoxidase antibodies (AbTPO).
    Giovanella L, Ceriani L, Garancini S.
    Q J Nucl Med; 2001 Mar; 45(1):115-9. PubMed ID: 11456370
    [Abstract] [Full Text] [Related]

  • 17. TSH receptor antibodies for confirming the diagnosis and prediction of remission duration, in newly diagnosed Graves' disease patients.
    Aleksić A, Aleksić Z, Stojanović M.
    Hell J Nucl Med; 2009 Mar; 12(2):146-50. PubMed ID: 19675869
    [Abstract] [Full Text] [Related]

  • 18. Comparison of a solid phase human- versus porcine- thyrotropin receptor-based immunoassay for the measurement of thyrotropin receptor antibodies in patients with thyroid diseases.
    Hermsen D, Liu C, Domberg J, Graeber C, Feldkamp J, Duan Y, Xu K, Liu C, Mao X, Scherbaum WA, Schott M.
    Exp Clin Endocrinol Diabetes; 2008 Sep; 116 Suppl 1():S59-63. PubMed ID: 18777457
    [Abstract] [Full Text] [Related]

  • 19. [Prospective study on the relationship between treatment duration of antithyroid drug and remission rate of Graves' disease].
    Liu C, Duan Y, Wu X.
    Zhonghua Yi Xue Za Zhi; 2000 Nov; 80(11):835-7. PubMed ID: 11218878
    [Abstract] [Full Text] [Related]

  • 20. [Antithyrotropin receptor antibodies in a series of Basedow's disease].
    Vidal E, Antoine E, Nadalon S, Cevallos R, Bournaud E, Vandroux JC, Bordessoule D, Loustaud V, Weinbreck P, Liozon F.
    Ann Med Interne (Paris); 1988 Nov; 139(5):331-5. PubMed ID: 2462393
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.